Intact FGF23 concentration in healthy infants, children, and adolescents, and diagnostic usefulness in patients with X-linked hypophosphatemic rickets
Open Access
- 22 November 2023
- journal article
- research article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 47 (4) , 873-882
Abstract
Objective: FGF23 measurement may have a diagnostic role to investigate patients with phosphate disorders. However, normal values for infants, children, and adolescents have not been defined. Methods: In a total of 282 (males 145, females 137) healthy infants (n = 30), prepubertal (n = 147), pubertal (n = 59), and postpubertal (n = 46), and in twenty patients with X-linked hypophosphatemic rickets (XLH, age 10.2 ± 5.6 years) serum phosphate (automated analyzer), and plasma intact FGF23 (immunochemiluminescent sandwich assay, DiaSorin) concentrations were measured. Results: Intact FGF23 concentrations were higher in healthy infants than in prepubertal (P < 0.01) and postpubertal subjects (P < 0.05); pubertal subjects showed higher values (P < 0.05) than postpubertal subjects. Serum phosphate concentrations were higher (P < 0.001) in healthy infants than in prepubertal, pubertal, and postpubertal subjects. Pubertal subjects had higher (P < 0.001) serum phosphate concentrations than postpubertal subjects. Intact FGF23 and serum phosphate concentrations did not differ (P = NS) by sex, age of menarche, and time after menarche. In healthy subjects, there was no correlation between intact FGF23 and serum phosphate concentrations. Intact FGF23 concentrations were higher (P < 0.0001) in patients with XLH than in healthy subjects according to chronological age and pubertal development. In all patients, intact FGF23 concentrations were above 40 pg/mL; intact FGF23 concentrations were inversely correlated with serum phosphate concentrations (r = −0.65; P < 0.01). Conclusion: In healthy subjects, chronological age and puberty were main determinants of intact FGF23 concentrations. Intact FGF23 concentrations may be a useful marker for the early diagnosis of XLH in pediatric patients.Keywords
Funding Information
- Università di Pisa
This publication has 47 references indexed in Scilit:
- The expanding family of hypophosphatemic syndromesJournal of Bone and Mineral Metabolism, 2011
- Evaluation of a new automated chemiluminescence immunoassay for FGF23Journal of Bone and Mineral Metabolism, 2011
- Circulating Levels of Soluble Klotho and FGF23 in X-Linked Hypophosphatemia: Circadian Variance, Effects of Treatment, and Relationship to Parathyroid StatusThe Journal of Clinical Endocrinology & Metabolism, 2010
- Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 ConcentrationsThe Journal of Clinical Endocrinology & Metabolism, 2010
- Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patientsBone, 2008
- The parathyroid is a target organ for FGF23 in ratsJournal of Clinical Investigation, 2007
- Fibroblast Growth Factor 23Journal of the American Society of Nephrology, 2005
- Circulating FGF-23 Is Regulated by 1α,25-Dihydroxyvitamin D3 and Phosphorus in VivoJournal of Biological Chemistry, 2005
- Cross sectional stature and weight reference curves for the UK, 1990.Archives of Disease in Childhood, 1995
- Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty.Archives of Disease in Childhood, 1976